Frontline Immunotherapy with Response-Guided Subsequent Treatment in Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Immunotherapy
Response-Guided Treatment
Treatment De-escalation
Bayesian Methods
A SoCO Research Forum presentation on the FIRST analysis, including dose intensity, early benefit, Bayesian causal inference, and treatment de-escalation in cutaneous squamous cell carcinoma.
Presentation
Frontline Immunotherapy with Response-Guided Subsequent Treatment (FIRST) in Cutaneous Squamous Cell Carcinoma
A Bayesian Causal Analysis of Dose Intensity, Early Benefit, and Treatment De-escalation
Presented at the Society of Cutaneous Oncology Research Forum in April 2026.
Summary
This Research Forum session reviewed the FIRST analysis in cutaneous squamous cell carcinoma, focusing on response-guided treatment, dose intensity, early clinical benefit, and the possibility of treatment de-escalation after frontline immunotherapy.
The discussion emphasized how Bayesian causal methods may help interpret non-randomized treatment patterns and generate clinically meaningful hypotheses about treatment duration, dose intensity, and response-adapted care.